Hemopressin Peptide Reduces Pain and Inflammation in Experimental Arthritis | Research

The takeaway

Hemopressin, a cannabinoid receptor inverse agonist peptide, reduced joint swelling, pain, and inflammation in a rat model of rheumatoid arthritis when given locally or orally.

Effective by both local and oral routes
Hemopressin reduced arthritis inflammation and pain comparable to indomethacin

What the researchers found

Hemopressin reduced arthritis-induced joint swelling, pain behavior, and inflammatory markers (MPO, leukocytes, IL-6) via both intra-articular and oral routes, independent of CGRP and substance P.

Why it matters

Rheumatoid arthritis affects millions and current treatments have significant side effects. A peptide targeting the endocannabinoid system that works both locally and orally could offer a novel therapeutic approach with a different safety profile.

The numbers in context

10-20 mcg/day i.art.; 20 mcg/kg oral; 4 days; reduced swelling, MPO, leukocytes, IL-6; SP and CGRP unchanged

How the study worked

Antigen-induced arthritis (AIA) in rats via intra-articular mBSA injection. Treatments: Hp (10/20 μg i.art. or 20 μg/kg oral) daily for 4 days. Measures: joint edema, gait analysis, leukocyte counts, cytokines, and spinal cord neuropeptide immunoreactivity.

Who was studied

Male Sprague Dawley rats with antigen-induced arthritis

What this study cannot tell us

Animal study — rat arthritis model may not fully represent human RA. Short 4-day treatment period. Small group sizes implied. Long-term safety and efficacy not assessed.

How to read the evidence

Well-designed preclinical study with multiple routes, doses, and outcome measures. Pre-clinical evidence requiring human translation.

When this study was published

Published in 2021, contributing to research on endocannabinoid system peptides for inflammatory conditions.

The bigger picture

Endocannabinoid system modulation for arthritis is an active area of research. Hemopressin offers an intriguing approach as a peptide-based cannabinoid receptor modulator that avoids the psychoactive effects associated with cannabinoid agonists while still providing anti-inflammatory and pain-relieving benefits.

Questions still open

Would hemopressin be effective in chronic arthritis models or human RA?
What is the optimal route and dosing for clinical hemopressin use?
How does hemopressin's anti-arthritic effect compare to existing biologics?

Common questions

What is hemopressin and how does it relate to cannabis?

Hemopressin is a naturally occurring peptide in the body that modulates the same receptor system (endocannabinoid system) as cannabis compounds. Unlike THC, it acts as an inverse agonist — reducing the receptor's baseline activity — and doesn't cause psychoactive effects while still providing anti-inflammatory benefits.

Could hemopressin become a treatment for rheumatoid arthritis?

This study shows promise: hemopressin reduced joint swelling, improved mobility, and lowered inflammatory markers in arthritic rats, working through both injection and oral routes. However, it needs to be tested in human clinical trials before it could become a treatment option.

Read the original research

The potential anti-inflammatory and anti-nociceptive effects of rat hemopressin (PVNFKFLSH) in experimental arthritis.

European journal of pharmacology, 890, 173636

View on PubMed ↗Publisher’s paper ↗

Citation

Camargo, Livia L; Denadai-Souza, Alexandre; Yshii, Lidia M; Lima, Carla; Teixeira, Simone A; Cerqueira, Anderson R A; Gewehr, Mayara C F; Fernandes, Elizabeth S; Schenka, André A; Muscará, Marcelo N; Ferro, Emer S; Costa, Soraia K P. (2021). The potential anti-inflammatory and anti-nociceptive effects of rat hemopressin (PVNFKFLSH) in experimental arthritis.. European journal of pharmacology, 890, 173636. https://doi.org/10.1016/j.ejphar.2020.173636